Search Results (327)

Silymarin—a standardized extract from the seeds of milk thistle (Silybum marianum L. Gaertn.)—is mainly used for the treatment of hepatitis and other liver diseases. In recent years, the attention of researchers has been directed to its use in dermatology and wound treatment. Despite the promising results, there are still many unresolved issues in this area. The aim of the present study is to develop and characterize hydrogel chitosan–pectin films containing silymarin as an active ingredient with potential medical application. Six variants of hydrogel films (control and silymarin-loaded) were obtained from chitosan and pectin solutions by the casting method and analyzed in terms of their physicochemical, structural, mechanical and optical properties, as well as the in vitro dissolution profile of silymarin. The highest tensile strength was measured for the chitosan-based films—23.35 ± 1.74 MPa (control) and 22.01 ± 2.67 MPa (silymarin-loaded), while the barrier properties to UV and visible light were the strongest for chitosan–pectin films with silymarin. The antioxidant potential of the films was determined by DPPH assay and it was found that the variants with silymarin have over 20 times higher antioxidant activity (from 2.020 ± 0.048 to 2.106 ± 0.190 mg TE/g) than the corresponding controls. The results showed that chitosan–pectin films with incorporated silymarin could find application as potential hydrogel dressings in the therapy of wounds and superficial burns. Full article

Background: Non-alcoholic steatohepatitis (NASH) lacks approved pharmacotherapies despite affecting approximately 25% of the global population. Agrimonia pilosa, a traditional herb with anti-inflammatory and antioxidant properties, remains unexplored for NASH treatment. Objective: This study investigated the hepatoprotective effects and mechanisms of Agrimonia pilosa extract (APE) in NASH models. Methods: HepG2 cells were treated with free fatty acids (0.125 mM) and APE (+12.5–50 μg/mL). C57BL/6J mice received a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) for 12 weeks with APE (25–100 mg/kg/day), silymarin (100 mg/kg/day), or luteolin (20 mg/kg/day). Lipid accumulation, liver enzymes, histopathology, and molecular markers were assessed. Results: APE dose-dependently reduced lipid accumulation in FFA-treated cells, suppressed lipogenic factors (SREBF1, CEBPA, and PPARG), and upregulated fatty acid oxidation enzymes (CPT1A and PPARA) via AMPK/SIRT1 activation. In NASH mice, APE (100 mg/kg) significantly decreased serum ALT (160.0 ± 49.1 vs. 311.2 ± 66.7 U/L) and AST (96.0 ± 18.7 vs. 219.0 ± 55.7 U/L, p < 0.001), reduced hepatic macrophage infiltration by 68%, and substantially attenuated inflammatory markers (Ccl2, Tnf, and IL6), oxidative stress indicators (NRF2, HMOX1, and CYBB), and fibrogenic markers (ACTA2, COL1A1, and TGFB1) by 83–85% (p < 0.001). Collagen deposition decreased from 5.63 ± 0.39% to 1.54 ± 0.03% (p < 0.001). Conclusions: APE exerts potent hepatoprotective effects through multi-targeted modulation of lipid metabolism, inflammation, oxidative stress, and fibrosis via AMPK/SIRT1 pathway activation, supporting its potential as a natural therapeutic intervention for NASH. Full article

This study aimed to determine the effect of lactic acid fermentation with Lactiplantibacillus plantarum on the bioactive compound composition and fatty acid profile of black cumin, camelina, milk thistle, and evening primrose cakes, as well as to evaluate their application as ingredients in wheat bread production (9% of wheat flour substitution). Fermentation increased the content of flavonoids and phenolic acids in camelina cake by approximately 30%, while causing a 30% decrease in carotenoid content. In black cumin cake, an eightfold increase in 4-hydroxybenzoic acid content and a 10% reduction in thymoquinone were observed. For milk thistle, silymarin content decreased by approximately 10%. Fermentation increased the proportion of saturated fatty acids (SFAs) and monounsaturated fatty acids (MUFAs), reducing polyunsaturated fatty acids (PUFAs) in all analyzed cakes. Breads containing 9% fermented cakes exhibited lower specific volume and greater hardness (22–80%), gumminess (17–64%), and chewiness (8–48%), compared to the breads with unfermented cakes. The contents of bioactive compounds in breads depended on the type of cake added. The bread with fermented camelina cake showed a 15% increase in flavonoid content and higher levels of selected phenolic acids compared to the bread with unfermented camelina. The breads containing camelina cake, both fermented and unfermented, also had the most favorable physical quality (texture and volume). The amount of ferulic acid in all samples of bread with the addition of fermented cakes was lower in comparison to the bread samples with unfermented cakes. Full article

Silymarin, a polyphenolic flavonolignan complex extracted from Silybum marianum (milk thistle), has long been recognized for its hepatoprotective, antioxidant, anti-inflammatory, and anticancer properties. Among its constituents, silybin is the most pharmacologically active and has been extensively studied in both preclinical and clinical settings. However, the clinical application of silymarin-based therapies remains limited by poor aqueous solubility, low oral bioavailability, rapid metabolism, and physicochemical instability. This review systematically outlines the pharmacokinetic challenges of silymarin and highlights recent advancements in formulation strategies designed to overcome these barriers. Key innovations include nanotechnology-enabled delivery systems, lipid-based carriers, water-soluble derivatives, bioavailability enhancers, parenteral and transdermal formulations, as well as controlled and synchronous release technologies. These approaches significantly improve tissue targeting, intracellular uptake, and pharmacological efficacy. Additionally, this review evaluates currently marketed silymarin formulations and recent clinical/preclinical evidence, revealing a persistent gap between laboratory advances and commercially available products. By synthesizing the mechanistic, regulatory, and manufacturability barriers that hinder translation, we delineate the key challenges that must be addressed to enable clinically deployable next-generation silymarin products. Collectively, these insights illustrate a paradigm shift in the modernization of phytomedicine, positioning silymarin as a model compound for the transformation of traditional herbal remedies into precision therapeutics through interdisciplinary drug delivery innovations. Full article

The search for natural alternatives that improve the productive efficiency and metabolic state of dairy cows has driven the use of phytogenic compounds such as silymarin, a flavonolignan extracted from Silybum marianum L. Gaertn with recognized antioxidant, anti-inflammatory, and hepatoprotective properties. This study evaluated the effects of silymarin supplementation on the productive performance; milk composition; and ruminal, hematological, biochemical, and oxidative parameters of lactating Jersey cows kept in a confined system with robotic milking. Twelve cows (230 ± 30 days in lactation; 22 ± 3.5 kg/day of milk) were distributed in a crossover design, receiving a control diet (GCON) or a diet supplemented with 5 g/cow/day of silymarin (GSIL) for 28 days in each stage. Silymarin intake did not alter dry matter intake, feed efficiency, or average milk production (p > 0.05), but it increased milk fat content (4.27 × 4.02%; p = 0.05) and, consequently, milk production corrected for 4% fat (24.4 × 23.2 kg/day; p = 0.05). In the rumen environment, cows in the GSIL group showed higher concentrations of acetic acid (57.4 × 48.4 nmol/L), and total short-chain fatty acids (100.2 × 89.4 nmol/L; p = 0.01). Regarding the biochemical profile, silymarin reduced gamma-glutamyltransferase and aspartate aminotransferase activities, as well as haptoglobin levels, indicating a hepatoprotective effect, combined with a lower inflammatory response in the liver. Oxidative status was improved by decreased levels of TBARS (lipid peroxidation) and reactive oxygen species, as well as myeloperoxidase activity in the serum of cows fed silymarin (p ≤ 0.05), but there was no difference between groups for superoxide dismutase activity and glutathione levels. The inclusion of silymarin in the diet of lactating Jersey cows improved the antioxidant and hepatic profile, increased milk fat content, and favored ruminal fermentation, suggesting metabolic and productive benefits in confined systems with high physiological demands. Full article

Cannibalism in Black-necked pheasants is a problem in aviary rearing, and an effective solution is still lacking. We performed the present study to investigate the potential of using tryptophan or silymarin to suppress cannibalism. The following types of investigations were performed: evaluation of the pheasants’ harmful behavior manifestations, and evaluation of the clinical forms, severity and localization of injuries of feathers and tissues, and neurohormonal manifestations. Additionally, the potential of cannibalism control in pheasants by supplementing tryptophan and silymarin to the birds’ diet was investigated. Ethological studies have shown a low intensity of feather pecking in pheasants without cannibalism manifestations. In pheasants with pronounced cannibalism, severe forms of feather and tissue pecking were observed in the head, back, wings, and rump areas, as well as specific forms affecting the tail feathers and the cloaca. Tryptophan and silymarin significantly reduced the levels of injurious pecking in the studied game birds and improved the healing of the lesions. The blood serotonin and dopamine levels in pheasants manifesting cannibalism were significantly lower than those in birds which did not show such behavior. The addition of tryptophan or silymarin to the diet of birds exhibiting cannibalism resulted in significantly increased plasma concentrations of serotonin or dopamine. Full article

Background/Objectives: PlantCrystals (PCs) are submicron particles derived from plants or parts of plants that can be produced by bead milling and/or high-pressure homogenization. Previous studies suggested improved dermal drug delivery of lipophilic active ingredients (API), which was explained by the formation of extracellular vesicles (EVs) during the production of PCs. The aim of this study was to investigate the suitability of PCs for enhancing the dermal penetration efficacy of different types of APIs. Methods: For this purpose, hydrophilic, lipophilic, and poorly water-soluble API-surrogates were loaded into PCs, and the dermal penetration efficacy, as well as the skin hydrating properties, were determined with an ex vivo porcine ear model. The penetration efficacy of the API surrogates from the PCs was compared to other formulation principles, e.g., simple API solutions, API loaded into classical EVs, and API added to the PCs after preparation. Silymarin-PCs—unloaded and loaded with API—were obtained by milling milk thistle seeds using small-scale bead milling. The PCs were characterized by size, size distribution, and zeta potential. Results: Milling of milk thistle seeds resulted in the formation of submicron particles with sizes of about 300 nm. Loaded PCs had a slightly larger size. Loading API into PCs resulted in improved dermal penetration when compared to the other formulation principles. The effect was most pronounced for the lipophilic API-surrogate (+90%, p < 0.001) and least pronounced for the hydrophilic API-surrogate (+2%, p > 0.05). The improved penetration of API from PCs can be explained by the formation of EVs during the production of the PCs in which the API is encapsulated. The encapsulation seemed to be highly efficient for the lipophilic API-surrogate, moderate for the poorly soluble API-surrogate, and very limited for the hydrophilic API-surrogate. All formulations increased the skin hydration significantly by about 30–40%. Conclusions: Milk thistle seeds are suitable for the production of PCs. These PCs improve skin hydration and enhance the dermal penetration of poorly water soluble and lipophilic APIs. However, they have limited effects on the dermal penetration efficacy of hydrophilic APIs. Full article

Chronic pain represents a major challenge for healthcare systems worldwide. Pharmacological agents such as opioids, gabapentinoids, and non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used depending on the pain type (nociceptive, neuropathic, or nociplastic), but their use is often limited by adverse effects. Nutraceuticals and dietary supplements have emerged as potential adjuvants to conventional pain management, offering improved safety profiles. This narrative review aims to evaluate the preliminary evidence on the efficacy and safety of selected plant-derived nutraceuticals for pain management. Particular attention is given to a new fixed nutraceutical formulation containing lycopene, sulforaphane (Brassica oleracea), silymarin (extracted from Silybum marianum), reduced glutathione, escin (Aesculus hippocastanum), tryptophan, and green tea (Camellia sinensis). Although this formulation has not yet been evaluated in clinical trials, preliminary data suggest that individual components may target different pain mechanisms. None of the currently available nutraceuticals act comprehensively on all pain types. Additionally, the inclusion of hepatoprotective compounds (e.g., glutathione and silymarin) may be advantageous for patients receiving multiple medications. Current evidence on these nutraceuticals remains limited and primarily preclinical. Further randomized controlled trials are needed to confirm their efficacy and safety in human pain management. Full article

Endometriosis involves oestrogen-dependent chronic inflammation and the abnormal proliferation of ectopic endometrial tissue. Conventional hormonal therapies suppress systemic oestrogen, but do not fully address local oxidative and inflammatory signalling. This review provides a mechanistic synthesis of recent molecular evidence. This evidence is on four FDA-recognized (Food and Drug Administration) medicinal plants. These are Curcuma longa, Zingiber officinale, Glycyrrhiza glabra, and Silybum marianum. The review highlights their capacity to modulate key intracellular pathways. These pathways are implicated in endometriosis. The review covers the integration of phytochemical-specific actions within NF-κB- (nuclear factor kappa-light-chain-enhancer of activated B cells), COX-2-(Cyclooxygenase-2), PI3K/Akt-(PI3K/Akt signaling pathway), Nrf2/ARE-(Nuclear factor erythroid 2–related factor 2) and ERβ-(Estrogen receptor beta) mediated networks, which jointly regulate cytokine secretion, apoptosis, angiogenesis and redox balance in endometrial lesions. Curcumin downregulates COX-2 and aromatase while activating Nrf2 signalling, shogaol from ginger suppresses prostaglandin synthesis and induces caspase-dependent apoptosis, isoliquiritigenin from liquorice inhibits HMGB1-TLR4–NF-κB (High Mobility Group Box 1, Toll-like receptor 4) activation, and silymarin from milk thistle reduces IL-6 (Interleukin-6) and miR-155 (microRNA-155) expression while enhancing antioxidant capacity. Together, these phytochemicals demonstrate pharmacodynamic complementarity with hormonal agents by targeting local inflammatory and oxidative circuits rather than systemic endocrine axes. This mechanistic framework supports the rational integration of phytotherapy into endometriosis management and identifies redox-inflammatory signalling nodes as future translational targets. Full article

Silymarin and L-carnitine are individually used in fish diets, yet whether they exert interactive or additive effects when combined remains unclear. This study aimed to investigate the individual and combined impacts of dietary silymarin (S), L-carnitine (LC), and their combination (S + LC) on growth performance, digestive enzyme activity, antioxidant status, immune response, and gene expression in Nile tilapia. A total of 360 fish (initial body weight: 10.01 ± 0.03 g) were randomly allocated into 12 fiberglass tanks (30 fish/tank) and fed one of four diets for 84 days: control (basal diet), S (850 mg/kg), LC (500 mg/kg), and S + LC (425 mg/kg S + 250 mg/kg LC). Fish fed S and S + LC diets exhibited significantly higher final body weight, weight gain, and specific growth rate (SGR), along with improved feed conversion ratio (FCR) compared to the control (p < 0.05). All supplemented groups exhibited enhanced digestive enzyme activities (amylase, lipase, protease), with the S + LC group showing the highest values. Serum biochemical profiles revealed increased total protein and globulin and reduced glucose and cortisol levels. Innate immune responses (IgM, lysozyme activity, NBT%, and bactericidal activity) were significantly elevated, especially in the S + LC group. Antioxidant enzyme activities (SOD, CAT, GPx) increased, while malondialdehyde (MDA) levels declined. Gene expression analysis showed significant upregulation of IGF-1, IFNA-1, SOD, CAT, and Gsr, with the greatest expression in the S + LC group. These findings indicate that dietary silymarin and L-carnitine, particularly when provided together, produced complementary and enhanced effects on growth, immune competence, antioxidant capacity, and gene regulation in Nile tilapia. Full article

An unhealthy prepubertal diet can have long-lasting effects throughout life. This study investigated hair concentrations of adrenal and sex steroids, in an in vivo mouse model of juvenile obesity subjected to control (CTRL), obesogenic (HFHC) diet, or nutraceutical supplementation (silymarin or coconut oil) diets. 87 3-week-old C57BL/6 mice (42 females, 45 males) were fed CTRL or HFHC diets for 8 weeks. Afterward, the CTRL group continued on CTRL diet while the HFHC diet group was divided into five groups: HFHC, HFHC→CTRL, HFHC→CTRL + silymarin (SIL), HFHC→HFHC + SIL and HFHC→HFHC + Coconut oil. At 4 weeks, the HFHC group showed increased cortisol/dehydroepiandrosterone (DHEA) ratio compared to CTRL group. At 20 weeks, the HFHC→HFHC group showed higher levels of progesterone (P4) and dehydroepiandrosterone sulfate (DHEA-S) and lower levels of estradiol (E2) compared to the CTRL→CTRL group. The switch from HFHC→CTRL was the optimal therapy because the body weight and almost all the hormones were close to those observed for the CTRL diet group. Supplement with SIL or Coconut oil reduced DHEA-S and increased in E2 compared with the endocrine setting seen with the HFHC diet. These interventions should be considered as supportive measures rather than substitutes for dietary correction. Full article

Background/Objectives: Cerebral ischemia and reperfusion injury, induced by bilateral common carotid artery occlusion and reperfusion (BCCAO/R), cause extensive neuronal damage and cognitive impairment. Bouvardia ternifolia (BtD), a plant known for its anti-inflammatory and neuroprotective effects, may offer therapeutic benefits against ischemic injury. This study aimed to evaluate the neuroprotective effects of BtD root extract on neuronal integrity, oxidative stress, and p53 protein expression following global cerebral ischemia in rats. Methods: Adult male Sprague Dawley rats were subjected to the BCCAO/R procedure for 60 min, followed by six days of reperfusion. Experimental groups included BCCAO/R+BtD, BCCAO/R+silymarin (reference control), BCCAO/R+vehicle, and sham controls. Neuronal morphology in the cortex, striatum, hippocampus, and cerebellum was assessed histologically. Oxidative stress markers, including reactive oxygen species (ROS), lipid peroxidation (LPO), reduced glutathione (GSH), and superoxide dismutase (SOD), were measured, along with the expression of p53 protein. Results: Treatment with BtD significantly decreased oxidative stress markers—LPO (82.2%), ROS (88.2%), GSH (66.5%), and SOD (54%)—and reduced p53 expression levels by 75%. Histological evaluation revealed that neurons in the BCCAO/R+BtD and BCCAO/R+silymarin groups maintained normal morphology, characterized by elongated cells and well-defined nuclei. In contrast, the BCCAO/R+vehicle group exhibited marked neuronal damage, including pyknosis, nuclear fragmentation, and interstitial edema, particularly in the hippocampal CA1 and cortical regions. BtD treatment significantly preserved neuronal structure and enhanced antioxidant defenses. Conclusions:Bouvardia ternifolia extract demonstrates neuroprotective potential in cerebral ischemia by maintaining neuronal architecture, reducing oxidative stress, and modulating p53 expression, supporting its therapeutic relevance in ischemia–reperfusion injury. Full article

Background/Objectives: Eleutherococcus senticosus (Siberian ginseng) is an adaptogenic plant widely recognized for its antioxidant and immunomodulatory properties; however its hepatoprotective potential properties are unexplored. This study aimed to evaluate whether the fruit extract of E. senticosus contains chemical constituents with hepatoprotective effects in a paracetamol-induced liver injury model in mice. Methods: Female BALB/c mice were randomized into five groups: control, paracetamol (300 mg/kg, IP), E. senticosus extract (750 or 1500 mg/kg, PO) + paracetamol, and silymarin (50 mg/kg) + paracetamol. Extracts were administered for seven days before paracetamol challenge. Biochemical markers (ALT, AST, urea, creatinine, protein, albumin) and hematological parameters were assessed, and organs were subjected to histopathological examination. Phytochemical characterization of the extract was performed using UHPLC-DAD-MS and ICP-OES. Results: The 750 mg/kg dose of E. senticosus extract maintained ALT, AST, urea, and creatinine levels close to control values, while the higher dose (1500 mg/kg) was less effective and showed an increase in serum urea. Both extract doses and silymarin attenuated creatinine elevation induced by paracetamol. No histopathological changes were detected in the kidneys or brains of treated animals. Phytochemical analysis revealed high contents of phenolic acids (chlorogenic and dicaffeoylquinic acids), flavonoids, amino acids, and essential minerals. Conclusions: E. senticosus fruit extract demonstrated a hepatoprotective effect at an optimal dose (750 mg/kg), indicating a potential dose-dependent effect. The absence of histopathological alterations in key organs supports the fruit extract’s safety. Full article

Silymarin, a flavonolignan-rich extract of Silybum marianum, is widely recognized for its hepatoprotective potential. While rodent studies predominate, pigs (Sus scrofa) offer a more translationally relevant model due to their hepatic architecture, bile acid composition, and transporter expression, which closely resemble those of humans. This narrative review synthesises current evidence on the chemistry, pharmacokinetics, biodistribution, and hepatoprotective activity of silymarin in porcine models. Available studies demonstrate that when adequate intrahepatic exposure is achieved, particularly through optimised formulations, silymarin can attenuate oxidative stress, suppress inflammatory signalling, stabilise mitochondria, and modulate fibrogenic pathways. Protective effects have been reported across diverse porcine injury paradigms, including toxin-induced necrosis, ethanol- and diet-associated steatosis, metabolic dysfunction, ischemia–reperfusion injury, and partial hepatectomy. However, the evidence base remains limited, with few long-term studies addressing fibrosis or regeneration, and methodological heterogeneity complicates the comparison of data across studies. Current knowledge gaps in silymarin research include inconsistent chemotype characterization among plant sources, limited reporting of unbound pharmacokinetic parameters, and variability in histological scoring criteria across studies, which collectively hinder cross-study comparability and mechanistic interpretation. Advances in analytical chemistry, transporter biology, and formulation design are beginning to refine the interpretation of exposure–response relationships. Advances in analytical chemistry, transporter biology, and formulation design are beginning to refine the interpretation of exposure–response relationships. In parallel, emerging computational approaches, including machine-learning-assisted chemotype fingerprinting, automated histology scoring, and Bayesian exposure modeling, are being explored as supportive tools to enhance reproducibility and translational relevance; however, these frameworks remain exploratory and require empirical validation, particularly in modeling enterohepatic recirculation. Collectively, current porcine evidence supports silymarin as a context-dependent yet credible hepatoprotective agent, highlighting priorities for future research to better define its therapeutic potential in clinical nutrition and veterinary practice. Full article

Gallbladder mucocele (GBM) in dogs is a condition characterized by the excessive accumulation of mucin within the gallbladder, potentially leading to bile duct obstruction and serious complications. While cholecystectomy remains the treatment of choice for symptomatic cases, medical management is often considered in dogs with subclinical GBM. This study evaluated the effects of different hepatoprotectants on disease progression in subclinical GBM. Sixty dogs diagnosed with GBM were randomly assigned to one of the three treatment groups: Group 1 (Ursodeoxycholic acid (UDCA) alone), Group 2 (S-adenosylmethionine (SAMe) and silymarin), and Group 3 (UDCA, SAMe, and silymarin). Hepatic biochemical markers (GGT, ALP, ALT, AST, bilirubin, cholesterol) and ultrasound parameters (gallbladder sludge percentage, liver echogenicity) were assessed at baseline, day 30, day 60, day 180, and day 365. Group 3 exhibited the most significant improvement, with substantial reductions in GGT, ALP, ALT, and AST levels (p < 0.05). Group 3 also demonstrated a significant decrease in gallbladder sludge percentage and improved liver echogenicity (p < 0.05). Group 1 showed mild improvement, whereas Group 2 had minimal impact on markers of cholestasis or gallbladder health. These findings suggest that a combination therapy of UDCA, SAMe, and silymarin may offer the most effective medical approach for managing subclinical GBM in dogs. Full article